Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    67
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA07 PREVAST 10-IPS G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
A07XA04 HIDRASEC INFANTS B Racecadotril - 10mg 10mg Granules for suspension 858,715 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
C10AA07 ROSUPHAR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
G04BE09 VERDA G Vardenafil (HCl) - 10mg 10mg Tablet, orally disintegrating 1,023,880 L.L
L04AA29 TRIJAN G Tofacitinib - 10mg 10mg Tablet, film coated 84,793,962 L.L
C10AA07 ROSUVAS G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 450,187 L.L
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 618,168 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 720,525 L.L
C10AA07 SINLIP G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 563,070 L.L
C10AA07 SUPERSTAT G Rosuvastatin (calcium) - 10mg 10mg Tablet, coated 517,379 L.L
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 499,142 L.L
G04CA01 XATRAL XL B Alfuzosin HCl - 10mg 10mg Tablet, prolonged release 1,061,636 L.L
G04CA01 ALFOCIN G Alfuzosin HCl - 10mg 10mg Tablet, extended release 858,779 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 10mg 10mg Tablet, film coated 212,327 L.L
G04CA01 ALFUZOSINE BIOGARAN LP G Alfuzosin HCl - 10mg 10mg Tablet, coated, prolonged release 1,115,389 L.L
L01EX08 LENVIMA B Lenvatinib - 10mg 10mg Capsule, hard 124,450,304 L.L
A02BC04 RAMEP G Rabeprazole (sodium) - 10mg 10mg Tablet, gastroresistant 795,310 L.L
G04CA01 APO-ALFUZOSIN G Alfuzosin HCl - 10mg 10mg Tablet 2,331,567 L.L
G04CA01 PROSTETROL G Alfuzosin HCl - 10mg 10mg Tablet, modified release 360,150 L.L
G04CA01 PROSTETROL G Alfuzosin HCl - 10mg 10mg Tablet, modified release 682,672 L.L
C02KX04 OPSUMIT B Macitentan - 10mg 10mg Tablet, film coated L.L
N05AD01 HALOPERIDOL G Haloperidol - 10mg 10mg Tablet 339,160 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 710,893 L.L
D10BA01 CURACNE G Isotretinoin - 10mg 10mg Capsule, soft gelatin 970,254 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
D10BA01 CURACNE G Isotretinoin - 10mg 10mg Capsule, soft gelatin 970,254 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 10mg 10mg Tablet, film coated 526,786 L.L
N06AX26 BRINTELLIX B Vortioxetine - 10mg 10mg Tablet, film coated 4,345,987 L.L
    ...
    67
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025